[go: up one dir, main page]

PE20240769A1 - Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 - Google Patents

Pirimidinil-pirazoles sustituidos como inhibidores de cdk2

Info

Publication number
PE20240769A1
PE20240769A1 PE2023003342A PE2023003342A PE20240769A1 PE 20240769 A1 PE20240769 A1 PE 20240769A1 PE 2023003342 A PE2023003342 A PE 2023003342A PE 2023003342 A PE2023003342 A PE 2023003342A PE 20240769 A1 PE20240769 A1 PE 20240769A1
Authority
PE
Peru
Prior art keywords
group
pharmaceutically acceptable
pyrimidinil
pyrazoles
substituted
Prior art date
Application number
PE2023003342A
Other languages
English (en)
Inventor
Philip D Ramsden
Jr Neil Bifulco
Natasja Brooijmans
Emanuele Perola
Richard Vargas
Steven Mark Wenglowsky
Douglas Wilson
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of PE20240769A1 publication Critical patent/PE20240769A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un compuesto representado por la formula (I) o una sal farmaceuticamente aceptable. En particular, se refiere a un compuesto de la formula (I), o una sal farmaceuticamente aceptable de esta, donde cada R1 se selecciona independientemente del grupo que consiste en halo, OH, CN, entre otros; cada R2 se selecciona independientemente del grupo que consiste en halo, OH, CN, entre otros; R3 es alquilo C1-C6 opcionalmente sustituido con 1 o 2 grupos, cada uno seleccionado independientemente del grupo que consiste en halo, OH, entre otros; m se selecciona del grupo que consiste en 0, 1, 2, 3 y 4; y n se selecciona del grupo que consiste en 0, 1 y 2. Ademas, se refiere a una composicion farmaceutica que comprende un portador farmaceuticamente aceptable y el compuesto de la formula I, o una sal farmaceuticamente aceptable de esta; y es util para tratar el cancer.
PE2023003342A 2021-06-16 2022-06-15 Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 PE20240769A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211426P 2021-06-16 2021-06-16
US202263327474P 2022-04-05 2022-04-05
PCT/US2022/033576 WO2022266190A1 (en) 2021-06-16 2022-06-15 Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors

Publications (1)

Publication Number Publication Date
PE20240769A1 true PE20240769A1 (es) 2024-04-17

Family

ID=82694316

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003342A PE20240769A1 (es) 2021-06-16 2022-06-15 Pirimidinil-pirazoles sustituidos como inhibidores de cdk2

Country Status (17)

Country Link
US (1) US20240287040A1 (es)
EP (1) EP4355742A1 (es)
JP (1) JP2024523892A (es)
KR (1) KR20240022609A (es)
AU (1) AU2022293861A1 (es)
BR (1) BR112023026538A2 (es)
CA (1) CA3224189A1 (es)
CL (1) CL2023003758A1 (es)
CO (1) CO2024000221A2 (es)
CR (1) CR20240014A (es)
DO (1) DOP2023000277A (es)
EC (1) ECSP24003566A (es)
IL (1) IL309013A (es)
MX (1) MX2023015245A (es)
PE (1) PE20240769A1 (es)
SA (1) SA523451905B1 (es)
WO (1) WO2022266190A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
TW202317574A (zh) 2021-06-28 2023-05-01 美商纜圖藥品公司 Ｃｄｋ２抑制劑
IL321433A (en) 2022-12-16 2025-08-01 Astrazeneca Ab Purines 2,6,9 trimethylated
WO2025117682A1 (en) 2023-12-01 2025-06-05 Blueprint Medicines Corporation Cyclin-dependent kinase 2 degraders
WO2025188779A1 (en) 2024-03-04 2025-09-12 Blueprint Medicines Corporation Cdk2 inhibitors for treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551948A1 (en) * 2004-01-09 2005-07-28 Novartis Ag Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
SI3302448T1 (sl) * 2015-06-04 2024-03-29 Aurigene Oncology Limited Substituirani heterociklični derivati kot inhibitorji cdk
WO2020205560A1 (en) * 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors

Also Published As

Publication number Publication date
CO2024000221A2 (es) 2024-01-25
CA3224189A1 (en) 2022-12-22
CR20240014A (es) 2024-05-07
ECSP24003566A (es) 2024-04-30
CL2023003758A1 (es) 2024-07-12
SA523451905B1 (ar) 2025-06-22
IL309013A (en) 2024-01-01
BR112023026538A2 (pt) 2024-03-05
DOP2023000277A (es) 2024-03-28
AU2022293861A1 (en) 2024-01-04
WO2022266190A1 (en) 2022-12-22
KR20240022609A (ko) 2024-02-20
JP2024523892A (ja) 2024-07-02
EP4355742A1 (en) 2024-04-24
MX2023015245A (es) 2024-01-19
US20240287040A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
PE20240769A1 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
CO2023017082A2 (es) Compuestos de tiadiazolilo unidos a un átomo de oxígeno como inhibidores de dna polimerasa θ
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
DOP2019000087A (es) Compuestos químicos
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
AR126251A1 (es) Inhibidores de cdk2
PE20201256A1 (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
CO2024017733A2 (es) Inhibidores macrocíclicos de kras para el tratamiento de cáncer
CO6180503A2 (es) Composiciones de inhibidores de chk1
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
CL2023002966A1 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
CO2022004286A2 (es) Inhibidor de diacilglicerol aciltransferasa 2
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
CL2022001887A1 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
PE20251755A1 (es) Inhibidores de pcsk9 y metodos de uso de estos
CL2022002511A1 (es) Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano.
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
CL2016000860A1 (es) Proceso par inhibir incrustaciones complejas de yeso para sistemas de lodos de minerales en aplicaciones hidrometalúrgicas que comprende un componente activo seleccionado entre un polímero de carboxilato y un ácido de poliamina.
PE20220376A1 (es) Compuestos triciclicos y su uso
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
PE20240776A1 (es) Compuestos terapeuticos y procedimientos